Arete Therapeutics launched in 2003 with a straightforward therapeutic and commercial goal: to develop a new treatment for high blood pressure that works by blocking the s-EH enzyme. Arete began enrolling patients for its first human trial in November 2007, and its oral inhibitor of s-EH proved safe. By the time the safety data were released a year later, Arete's strategy had been further refined and the company was envisioning the compound as a potential therapy for metabolic syndrome. Based on data from preclinical studies, Arete now posits that its therapy can become a treatment for type 2 diabetes.
3912 Trust Way
Hayward, CA 94545
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.
